Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Driving up immunity at tumor site may help enhance immunotherapy treatments

Driving up the immune response at the site of a cancer tumor with nanotechnology may help enhance immunotherapy treatments in advanced stages of the disease, new research in mice suggests.

14 Dec 2021

Study reveals molecular players involved in the onset of leukemia

A new study led by João T. Barata from Instituto de Medicina Molecular João Lobo Antunes (iMM, Portugal), and J. Andrés Yunes from Centro Infantil Boldrini (Brazil), published now in the scientific journal Nature Communications, shows that changes in a protein called IL-7R are sufficient to initiate a type of leukemia.

14 Dec 2021

Lymphoma patients can benefit from early CAR T treatment, study shows

Chimeric antigen receptor T-cell therapy or CAR T is a breakthrough treatment for patients with certain types of blood cancers.

13 Dec 2021

$Study finds new treatment option for patients with relapsed or refractory peripheral T-cell lymphoma$

Study finds new treatment option for patients with relapsed or refractory peripheral T-cell lymphoma

The final results from a national phase 2 study including researchers from Yale Cancer Center show the drug tipifarnib increased survival rates for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

13 Dec 2021

Study offers new hope for large B-cell lymphoma patients

Of the 18,000 people diagnosed with large B-cell lymphoma each year, only half will be successfully treated with chemotherapy. The 9,000 remaining patients typically have poor outcomes, with only 25% responding to additional, higher-intensity chemotherapy, followed by a stem cell transplant.

13 Dec 2021

Clinical studies show enhanced responses for lymphoma patients treated with axi-cel CAR T cell therapy

Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T cell therapy.

12 Dec 2021

Indication of minor added benefit of nivolumab for adjuvant treatment of esophageal cancer

In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care investigated whether nivolumab has an added benefit over watchful waiting in the adjuvant treatment of adults with carcinoma of the esophagus or the gastroesophageal junction and pathological residual disease after prior neoadjuvant chemoradiotherapy (CRT).

10 Dec 2021

Epigenetic clocks have potential as biomarkers of COVID-19 vaccine responses

New findings have important implications for research into the impact of COVID-19 and the mRNA vaccination on epigenetic aging in the immune system.

7 Dec 2021

Mutations in a crucial gene responsible for chemotherapy failure in some blood cancer patients

Mutations in a crucial gene are the key reason that chemotherapy fails in some patients with blood cancer, a study by Nanyang Technological University, Singapore (NTU Singapore) and Singapore General Hospital (SGH) has found.

6 Dec 2021

New genetic technology for gene expression analysis of cancer cells

In this interview, News-Medical speaks to Dr. Rong Lu about her recent research into the development of a new genetic technology for gene expression analysis of cancer cells.

3 Dec 2021

DNA sequencing of residual disease accurately identifies leukemia patients who would relapse

In pediatric and young adult patients with acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel (Kymriah), DNA sequencing-based detection of residual disease between three and 12 months accurately identified all patients who would eventually relapse, while other methods were less predictive.

1 Dec 2021

Study analyzes the resistance of H. pylori bacterium to antibiotics

A UPV/EHU study analyses the resistance of the Helicobacter pylori (H. pylori) bacterium to the antibiotics routinely used to treat the infection caused by this bacterium.

29 Nov 2021

NYU Langone opens new state-of-the-art center to treat patients with blood cancers

NYU Langone Health's Laura and Isaac Perlmutter Cancer Center opened a new state-of-the-art center to treat people with blood cancers, including leukemia, lymphoma, and multiple myeloma.

29 Nov 2021

International collaboration secures €1M grant to investigate new treatment target for lymphoma

An international collaboration involving researchers from Queen Mary University of London, Memorial Sloan Kettering Cancer Center, New York and Dana-Farber Cancer Institute, Boston has secured a €1M research grant from Dutch blood cancer charity, Lymph&Co, to investigate a new treatment target for lymphoma.

25 Nov 2021

CIRM awards $4.1 million to advance CAR T-cell therapy from the lab to clinic

On November 23, 2021, the California Institute for Regenerative Medicine (CIRM) governing board approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.

24 Nov 2021

Lymphoma News and Research

Further Reading

Driving up immunity at tumor site may help enhance immunotherapy treatments

Study reveals molecular players involved in the onset of leukemia

Lymphoma patients can benefit from early CAR T treatment, study shows

Study finds new treatment option for patients with relapsed or refractory peripheral T-cell lymphoma

Study offers new hope for large B-cell lymphoma patients

Clinical studies show enhanced responses for lymphoma patients treated with axi-cel CAR T cell therapy

Indication of minor added benefit of nivolumab for adjuvant treatment of esophageal cancer

Epigenetic clocks have potential as biomarkers of COVID-19 vaccine responses

Mutations in a crucial gene responsible for chemotherapy failure in some blood cancer patients

New genetic technology for gene expression analysis of cancer cells

DNA sequencing of residual disease accurately identifies leukemia patients who would relapse

Study analyzes the resistance of H. pylori bacterium to antibiotics

NYU Langone opens new state-of-the-art center to treat patients with blood cancers

International collaboration secures €1M grant to investigate new treatment target for lymphoma

CIRM awards $4.1 million to advance CAR T-cell therapy from the lab to clinic

Using PET scans to predict recurrence in Hodgkin lymphoma

Study may help predict genomic changes that may happen in advanced cancers based on therapy

COVID-19 booster shot extremely beneficial for most cancer patients

SARS-CoV-2 replicates in human placenta with release of infectious viral particles

Researchers identify gene expression involved in cancer progression and chemotherapy resistance

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News